Compare Stocks → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AVRONASDAQ:GNFTNASDAQ:MGTXNASDAQ:PRVLNASDAQ:REPL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVROAVROBIO$1.24+1.6%$1.28$0.57▼$1.70$55.63M1.22280,783 shs36,515 shsGNFTGenfit$3.45-5.0%$3.62$2.89▼$4.75$171.91M1.0815,488 shs3,488 shsMGTXMeiraGTx$5.01-4.6%$5.99$3.49▼$8.35$321.74M1.29154,734 shs235,243 shsPRVLPrevail Therapeutics$23.00$23.01$9.02▼$23.35$787.66M1.59955,800 shsN/AREPLReplimune Group$6.97-3.3%$7.98$5.89▼$24.81$427.89M1.211.36 million shs1.13 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVROAVROBIO+1.64%-2.36%-1.59%-6.77%+33.33%GNFTGenfit-0.29%-5.74%+0.88%+3.29%-9.22%MGTXMeiraGTx-4.57%-12.57%-20.22%-18.14%-8.41%PRVLPrevail Therapeutics0.00%0.00%0.00%0.00%0.00%REPLReplimune Group-3.33%-3.06%-15.62%-7.31%-58.66%You’re invited: Biggest crypto event of 2024 (Ad)During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVROAVROBIO1.8288 of 5 stars3.03.00.00.02.81.70.6GNFTGenfit0.7983 of 5 stars3.53.00.00.00.60.00.0MGTXMeiraGTx3.8626 of 5 stars3.54.00.04.80.01.70.6PRVLPrevail TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AREPLReplimune Group3.9828 of 5 stars3.51.00.04.51.13.31.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVROAVROBIO2.00Hold$2.0061.29% UpsideGNFTGenfit3.00Buy$11.00218.84% UpsideMGTXMeiraGTx3.00Buy$25.67412.31% UpsidePRVLPrevail TherapeuticsN/AN/AN/AN/AREPLReplimune Group3.00Buy$37.67440.41% UpsideCurrent Analyst RatingsLatest MGTX, REPL, AVRO, GNFT, and PRVL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/5/2024GNFTGenfitHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.003/15/2024MGTXMeiraGTxRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVROAVROBION/AN/A$0.28 per share4.40$2.13 per shareN/AGNFTGenfit$41.31M4.16N/AN/A$1.48 per share2.33MGTXMeiraGTx$14.02M22.95N/AN/A$2.17 per share2.31PRVLPrevail TherapeuticsN/AN/AN/AN/A$4.85 per shareN/AREPLReplimune GroupN/AN/AN/AN/A$9.80 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVROAVROBIO$12.16M-$0.10N/AN/AN/AN/A-74.86%-65.11%5/9/2024 (Estimated)GNFTGenfit-$31.27MN/A0.00N/AN/AN/AN/AN/A7/4/2024 (Estimated)MGTXMeiraGTx-$84.03M-$1.47N/A5.57N/A-599.47%-114.33%-42.56%5/9/2024 (Estimated)PRVLPrevail Therapeutics-$63.19M-$2.22N/AN/AN/AN/A-55.57%-48.14%N/AREPLReplimune Group-$174.28M-$3.16N/AN/AN/AN/A-42.94%-35.80%5/16/2024 (Estimated)Latest MGTX, REPL, AVRO, GNFT, and PRVL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/14/2024Q4 2023MGTXMeiraGTx-$0.46-$0.47-$0.01-$1.36$10.13 million$2.04 million2/8/2024Q3 2024REPLReplimune Group-$0.89-$0.77+$0.12-$0.77N/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVROAVROBION/AN/AN/AN/AN/AGNFTGenfitN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/APRVLPrevail TherapeuticsN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVROAVROBION/A15.7815.78GNFTGenfit0.922.942.94MGTXMeiraGTx0.622.382.38PRVLPrevail TherapeuticsN/A7.567.56REPLReplimune Group0.1612.4012.40OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVROAVROBIO62.63%GNFTGenfit2.24%MGTXMeiraGTx67.48%PRVLPrevail Therapeutics86.80%REPLReplimune Group92.53%Insider OwnershipCompanyInsider OwnershipAVROAVROBIO9.20%GNFTGenfit4.20%MGTXMeiraGTx9.70%PRVLPrevail Therapeutics57.20%REPLReplimune Group20.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAVROAVROBIO1344.86 million40.73 millionOptionableGNFTGenfit15449.83 million47.74 millionNot OptionableMGTXMeiraGTx41964.22 million57.99 millionOptionablePRVLPrevail Therapeutics6634.25 millionN/ANot OptionableREPLReplimune Group28461.39 million48.74 millionOptionableMGTX, REPL, AVRO, GNFT, and PRVL HeadlinesSourceHeadlineHead to Head Survey: Replimune Group (NASDAQ:REPL) vs. CG Oncology (NASDAQ:CGON)americanbankingnews.com - April 13 at 1:30 AMVanguard Group Inc. Increases Stake in Replimune Group, Inc. (NASDAQ:REPL)marketbeat.com - April 10 at 4:00 AMInterim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meetingglobenewswire.com - April 7 at 5:00 PMReplimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - April 4 at 8:00 AMFive things: Downtown building sale, nursing home lawsuit, Fast 50 and the clock is tickingbizjournals.com - March 30 at 9:59 AMReplimune appoints new CEO ahead of drug applicationuk.investing.com - March 29 at 12:50 AMPetri Dish: NIH sends BioNTech notice of default; Intellia ends Regeneron dealbizjournals.com - March 28 at 9:48 AMReplimune Names Sushil Patel as CEO in Broader Shakeupmarketwatch.com - March 26 at 12:12 PMReplimune Promotes Sushil Patel To Succeed Philip Astley-Sparke As CEOmarkets.businessinsider.com - March 26 at 12:12 PMReplimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitionsglobenewswire.com - March 26 at 7:30 AMReplimune Group (NASDAQ:REPL) Stock Price Up 5.3%marketbeat.com - March 21 at 4:24 PMREPL Apr 2024 10.000 callfinance.yahoo.com - March 16 at 12:31 PMREPL Mar 2024 10.000 putfinance.yahoo.com - March 15 at 4:28 PMHow Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%zacks.com - March 11 at 10:56 AMWhat Makes Replimune Group, Inc. (REPL) a New Buy Stockzacks.com - March 8 at 1:01 PMReplimune to Present at the American Association for Cancer Research Annual Meeting 2024finance.yahoo.com - March 6 at 7:31 PMReplimune to Present at Three Upcoming Investor Conferencesfinance.yahoo.com - March 5 at 10:04 AMWall Street Analysts See a 70.57% Upside in Replimune Group, Inc. (REPL): Can the Stock Really Move This High?zacks.com - February 23 at 10:56 AMPositive Outlook for Replimune Group with Buy Rating and Increased Price Target Amidst Promising RP1 + Opdivo Therapy Trialsmarkets.businessinsider.com - February 15 at 6:48 PMAnalysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Replimune Group (REPL) and Phibro Animal Health (PAHC)markets.businessinsider.com - February 9 at 7:41 AMReplimune Group Is Worried About This – Should You Be Worried Too?msn.com - February 9 at 7:41 AMReplimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Updatefinance.yahoo.com - February 8 at 11:10 AMReplimune Group Inc (REPL) Reports Fiscal Q3 2024 Results and Extends Cash Runwayfinance.yahoo.com - February 8 at 11:10 AMReplimune Group Inc (REPL)investing.com - February 8 at 12:00 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come5 Top-Rated Dividend Stocks With Double-Digit UpsideMarch 25, 2024 11:19 AMView 5 Top-Rated Dividend Stocks With Double-Digit Upside3 High Dividend Stocks to Replace Lower Savings Yields AheadApril 9, 2024 9:15 AMView 3 High Dividend Stocks to Replace Lower Savings Yields AheadAll Headlines Company DescriptionsAVROBIONASDAQ:AVROAVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.GenfitNASDAQ:GNFTGenfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.MeiraGTxNASDAQ:MGTXMeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Prevail TherapeuticsNASDAQ:PRVLPrevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.Replimune GroupNASDAQ:REPLReplimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.